Cancer

Theralase(R) Release’s 2Q2024 Financial Statements

TORONTO, ON / ACCESSWIRE / August 12, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage…

2 years ago

Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024

WOBURN, MA / ACCESSWIRE / August 9, 2024 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of…

2 years ago

Invenio Imaging Announces First Patients Enrolled in US Pivotal Study of AI-Based Image Analysis Module for Lung Cancer

SANTA CLARA, Calif., Aug. 9, 2024 /PRNewswire/ -- Invenio Imaging, a leader in intraoperative fresh tissue imaging and artificial intelligence…

2 years ago

Optellum Achieves ISO 27001:2022 Certification

OXFORD, United Kingdom, Aug. 9, 2024 /PRNewswire/ -- Optellum, a global leader in AI-powered early lung disease diagnosis & precision care,…

2 years ago

Applied DNA Announces Third Quarter Fiscal Year 2024 Financial Results

- Conference Call/Webcast Scheduled for Today at 4:30 PM ET - STONY BROOK, NY / ACCESSWIRE / August 8, 2024…

2 years ago

Cosmos Health Completes Registration Process in Germany to Commence Sales of its C-Scrub Antimicrobial Wash; Enters $750M+ Market

CHICAGO, IL / ACCESSWIRE / August 8, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…

2 years ago

Innovative Anti-Nausea Smartwatch EmeTerm® Smart Set to Launch on Indiegogo

VANCOUVER, BC, Aug. 8, 2024 /PRNewswire/ -- EmeTerm® Smart uses patented hybrid technology to seamlessly integrate the functionality of a…

2 years ago

LSU Athletics Becomes First College Sports Program to Use AI-Enabled Digital Stethoscopes From Eko Health to Care for Student-Athletes

Eko Health outfits LSU Athletic Sports Medicine team with CORE 500 digital stethoscopes and AI algorithms for the enhanced detection…

2 years ago

Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update

SEATTLE, WA / ACCESSWIRE / August 8, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing…

2 years ago

Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update

Company gained CE Mark approval for four of its women’s health products and completed buildout of commercial team for its…

2 years ago